IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation

IRS proteins are scaffolds that can activate survival signalling pathways. In this study, the authors identified IRS4 as a potential oncogene in breast cancer that leads to the constitutive activation of PI3K/AKT signalling and thus confers resistance to HER2-targeted therapy.

Guardado en:

Detalles Bibliográficos
Autores principales:	Gerjon J. Ikink, Mandy Boer, Elvira R. M. Bakker, John Hilkens
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7589cf0b1b644bf996fe00987062fff0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7589cf0b1b644bf996fe00987062fff0
record_format	dspace
spelling	oai:doaj.org-article:7589cf0b1b644bf996fe00987062fff02021-12-02T17:31:34ZIRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation10.1038/ncomms135672041-1723https://doaj.org/article/7589cf0b1b644bf996fe00987062fff02016-11-01T00:00:00Zhttps://doi.org/10.1038/ncomms13567https://doaj.org/toc/2041-1723IRS proteins are scaffolds that can activate survival signalling pathways. In this study, the authors identified IRS4 as a potential oncogene in breast cancer that leads to the constitutive activation of PI3K/AKT signalling and thus confers resistance to HER2-targeted therapy.Gerjon J. IkinkMandy BoerElvira R. M. BakkerJohn HilkensNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-15 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Gerjon J. Ikink Mandy Boer Elvira R. M. Bakker John Hilkens IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
description	IRS proteins are scaffolds that can activate survival signalling pathways. In this study, the authors identified IRS4 as a potential oncogene in breast cancer that leads to the constitutive activation of PI3K/AKT signalling and thus confers resistance to HER2-targeted therapy.
format	article
author	Gerjon J. Ikink Mandy Boer Elvira R. M. Bakker John Hilkens
author_facet	Gerjon J. Ikink Mandy Boer Elvira R. M. Bakker John Hilkens
author_sort	Gerjon J. Ikink
title	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
title_short	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
title_full	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
title_fullStr	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
title_full_unstemmed	IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
title_sort	irs4 induces mammary tumorigenesis and confers resistance to her2-targeted therapy through constitutive pi3k/akt-pathway hyperactivation
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/7589cf0b1b644bf996fe00987062fff0
work_keys_str_mv	AT gerjonjikink irs4inducesmammarytumorigenesisandconfersresistancetoher2targetedtherapythroughconstitutivepi3kaktpathwayhyperactivation AT mandyboer irs4inducesmammarytumorigenesisandconfersresistancetoher2targetedtherapythroughconstitutivepi3kaktpathwayhyperactivation AT elvirarmbakker irs4inducesmammarytumorigenesisandconfersresistancetoher2targetedtherapythroughconstitutivepi3kaktpathwayhyperactivation AT johnhilkens irs4inducesmammarytumorigenesisandconfersresistancetoher2targetedtherapythroughconstitutivepi3kaktpathwayhyperactivation
_version_	1718380560042164224

IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation

Ejemplares similares